News
CYCN
3.370
-20.71%
-0.880
Weekly Report: what happened at CYCN last week (0831-0904)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 4d ago
Weekly Report: what happened at CYCN last week (0824-0828)?
Weekly Report · 08/31 09:02
Cyclerion Shareholders Approve Key Measures for Korsana Merger
TipRanks · 08/27 10:27
Cyclerion Therapeutics Details Merger-Related Risks and Uncertainties
TipRanks · 08/25 20:51
Weekly Report: what happened at CYCN last week (0817-0821)?
Weekly Report · 08/24 09:02
Weekly Report: what happened at CYCN last week (0810-0814)?
Weekly Report · 08/17 09:02
Weekly Report: what happened at CYCN last week (0803-0807)?
Weekly Report · 08/10 09:02
Weekly Report: what happened at CYCN last week (0727-0731)?
Weekly Report · 08/03 09:02
Weekly Report: what happened at CYCN last week (0720-0724)?
Weekly Report · 07/27 09:02
Weekly Report: what happened at CYCN last week (0713-0717)?
Weekly Report · 07/20 09:02
Weekly Report: what happened at CYCN last week (0706-0710)?
Weekly Report · 07/13 09:02
Weekly Report: what happened at CYCN last week (0629-0703)?
Weekly Report · 07/06 09:02
Weekly Report: what happened at CYCN last week (0622-0626)?
Weekly Report · 06/29 09:02
Weekly Report: what happened at CYCN last week (0615-0619)?
Weekly Report · 06/22 09:02
Weekly Report: what happened at CYCN last week (0608-0612)?
Weekly Report · 06/15 09:02
Weekly Report: what happened at CYCN last week (0601-0605)?
Weekly Report · 06/08 09:02
Weekly Report: what happened at CYCN last week (0525-0529)?
Weekly Report · 06/01 09:02
Weekly Report: what happened at CYCN last week (0518-0522)?
Weekly Report · 05/25 09:02
More
Webull provides a variety of real-time CYCN stock news. You can receive the latest news about Cyclerion Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CYCN
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.